Vol 5, No 6 (December 29, 2016): Translational Lung Cancer Research (Emerging Treatment Options for Brain Metastases from Non-small Cell Lung Cancer)

Preface

Preface on “Emerging treatment options for brain metastases from non-small cell lung cancer”
Giulio Metro, Rita Chiari
Translational Lung Cancer Research  
2016;
5
(6)
:561-562
.

Review Article

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future
Claudia Proto, Martina Imbimbo, Rosaria Gallucci, Angela Brissa, Diego Signorelli, Milena Vitali, Marianna Macerelli, Giulia Corrao, Monica Ganzinelli, Francesca Gabriella Greco, Marina Chiara Garassino, Giuseppe Lo Russo
Translational Lung Cancer Research  
2016;
5
(6)
:563-578
.
Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC
Lorenza Landi, Federico Cappuzzo
Translational Lung Cancer Research  
2016;
5
(6)
:579-587
.
Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy
Panagiota Economopoulou, Giannis Mountzios
Translational Lung Cancer Research  
2016;
5
(6)
:588-598
.
State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer
Alessandro Inno, Vincenzo Di Noia, Ettore D’Argento, Alessandra Modena, Stefania Gori
Translational Lung Cancer Research  
2016;
5
(6)
:599-609
.
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer
Consuelo Buttigliero, Valentina Bertaglia, Silvia Novello
Translational Lung Cancer Research  
2016;
5
(6)
:610-627
.
Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives
Grainne M. O’Kane, Natasha B. Leighl
Translational Lung Cancer Research  
2016;
5
(6)
:628-636
.
Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases
Alessandra Fabi, Antonello Vidiri
Translational Lung Cancer Research  
2016;
5
(6)
:637-646
.

Controversies on Lung Cancer: Pros and Cons (Section Chairs: Suresh Senan, Helmut H. Popper)

Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung cancer, radiological suspicion of a local recurrence can be sufficient indication to proceed to salvage therapy
Timothy K. Nguyen, David A. Palma
Translational Lung Cancer Research  
2016;
5
(6)
:647-650
.
Cons: After lung stereotactic ablative radiotherapy for a peripheral stage I non-small cell lung carcinoma, radiological suspicion of a local recurrence is not sufficient indication to proceed to salvage therapy
Meredith Giuliani, Andrea Bezjak
Translational Lung Cancer Research  
2016;
5
(6)
:651-654
.
Rebuttal from Dr. Nguyen and Dr. Palma
Timothy K. Nguyen, David A. Palma
Translational Lung Cancer Research  
2016;
5
(6)
:655-657
.
Rebuttal from Dr. Bezjak and Dr. Giuliani
Meredith Giuliani, Andrea Bezjak
Translational Lung Cancer Research  
2016;
5
(6)
:658-659
.

Editorial

ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer
Viola W. Zhu, Sai-Hong Ignatius Ou
Translational Lung Cancer Research  
2016;
5
(6)
:660-664
.

Original Article

Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing
Clara Pérez-Barrios, Irene Nieto-Alcolado, María Torrente, Carolina Jiménez-Sánchez, Virginia Calvo, Lourdes Gutierrez-Sanz, Magda Palka, Encarnación Donoso-Navarro, Mariano Provencio, Atocha Romero
Translational Lung Cancer Research  
2016;
5
(6)
:665-672
.
Impact of dose calculation models on radiotherapy outcomes and quality adjusted life years for lung cancer treatment: do we need to measure radiotherapy outcomes to tune the radiobiological parameters of a normal tissue complication probability model?
Abdulhamid Chaikh, Nicolas Docquière, Pierre-Yves Bondiau, Jacques Balosso
Translational Lung Cancer Research  
2016;
5
(6)
:673-680
.
Statistic and dosimetric criteria to assess the shift of the prescribed dose for lung radiotherapy plans when integrating point kernel models in medical physics: are we ready?
Abdulhamid Chaikh, Jacques Balosso
Translational Lung Cancer Research  
2016;
5
(6)
:681-687
.
Statistical control process to compare and rank treatment plans in radiation oncology: impact of heterogeneity correction on treatment planning in lung cancer
Abdulhamid Chaikh, Jacques Balosso
Translational Lung Cancer Research  
2016;
5
(6)
:688-694
.

Review Article

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance
Roberta Minari, Paola Bordi, Marcello Tiseo
Translational Lung Cancer Research  
2016;
5
(6)
:695-708
.

Case Report

A rare case of palatin tonsillar metastasis from small cell lung cancer
Chiara D’Antonio, Alberto Lombardini, Concetta Elisa Onesti, Rosa Falcone, Adriana Romiti, Marianna Lombardi, Salvatore Lauro, Paolo Marchetti
Translational Lung Cancer Research  
2016;
5
(6)
:709-711
.
Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature
Concetta Elisa Onesti, Daniela Iacono, Silvia Angelini, Salvatore Lauro, Marco Mazzotta, Mario Alberto Occhipinti, Raffaele Giusti, Paolo Marchetti
Translational Lung Cancer Research  
2016;
5
(6)
:712-719
.
Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature
Chul Kim, Arun Rajan, Pedro A. Debrito, Giuseppe Giaccone
Translational Lung Cancer Research  
2016;
5
(6)
:720-726
.

Perspective

Metastatic lung cancer in the age of targeted therapy: improving long-term survival
Jaydira Del Rivero, Lindsey Enewold, Anish Thomas
Translational Lung Cancer Research  
2016;
5
(6)
:727-730
.

Disclosure:

The focused issue “Emerging Treatment Options for Brain Metastases from Non-small Cell Lung Cancer” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Giulio Metro and Rita Chiari served as the unpaid Guest Editors for the focused issue.